Decellularized Stem Cell Sheet for Tendon Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell-based therapies for musculoskeletal and connective tissue repair face challenges such as low stability, viability, and risk of uncontrolled cell action, along with high manufacturing costs and safety concerns, particularly in promoting tendon graft healing after anterior cruciate ligament reconstruction (ACLR).
Innovation Solution
The development of decellularized stem cell sheets, specifically decellularized tendon-derived stem cell (TDSC) sheets, which retain ultrastructural and biological cues, express growth factors like BMP-2 and VEGF, and provide biochemical and physical protection during healing, eliminating the need for synthetic scaffolds and reducing immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cell sheets are used to promote tissue repair, then growth-promoting and angiogenic effects are improved, but stability and viability control become problematic
Solution Approach 1:
The patent extracts the beneficial biological factors (growth factors, cytokines, ECM components) from living stem cells through decellularization, retaining these factors in the ECM scaffold while removing the cellular components that cause instability and viability control issues. This allows the therapeutic effects to be preserved without the problems of maintaining live cell stability.
Solution Approach 2:
The patent creates a decellularized scaffold that copies the structural and biochemical features of living stem cell sheets, including the ECM architecture and embedded bioactive factors, without requiring living cells. This replica provides the same tissue repair benefits while eliminating the need to maintain cell viability during storage and transport.
2Reliability
If living stem cells are transplanted for tissue regeneration, then immunomodulatory effects are improved, but immunogenicity and safety concerns increase
Solution Approach 1:
The patent removes cell membrane receptors and immunogenic cellular components through decellularization while retaining the immunomodulatory factors within the ECM. This extraction process eliminates the harmful immunogenicity associated with living stem cells while preserving the beneficial immunomodulatory effects through retained cytokines and growth factors.
3Reliability
If stem cell sheets are manufactured and transported, then tissue repair capability is maintained, but logistics complexity and cost increase
Solution Approach 1:
The patent employs decellularized scaffolds that can be manufactured, stored, and transported without complex viability maintenance requirements. These scaffolds function as disposable or storable therapeutic products that do not require the complex logistics chain needed for living cell products, significantly simplifying transportation and storage infrastructure.
Solution Approach 2:
The patent changes the physical and biological state of the stem cell product from living cells to decellularized scaffolds. This parameter change from viable cells to stabilized ECM structures fundamentally alters the storage and transport requirements, allowing standard refrigeration or even room temperature storage without the complex temperature control and time constraints of live cell logistics.
Data Source
AI summary
The subject invention pertains to a decellularized stem cell sheet and compositions thereof with retained biological activity. The present invention further relates to the optimized method of producing the decellularized stem cell sheet and methods of using the decellularized stem cell sheet for the promotion of tissue repair in a subject.